Apricus Biosciences

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus recently completed enrollment in a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Apricus’ lead commercial product, Vitaros®, for the treatment of ED, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation room temperature Vitaros is under development. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Size (employees)
15 (est)-37%
Apricus Biosciences is headquartered in San Diego, US

Apricus Biosciences Office Locations

Apricus Biosciences has an office in San Diego
San Diego, US (HQ)
300 11975 El Camino Real

Apricus Biosciences Data and Metrics

Apricus Biosciences Financial Metrics

Apricus Biosciences's revenue was reported to be $5.8 m in FY, 2016
USD

Net income (Q1, 2017)

8.1 m

Market capitalization (21-Sep-2017)

18.8 m

Cash (31-Mar-2017)

3.8 m
Apricus Biosciences's current market capitalization is $18.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.5 m9.3 m4.8 m5.8 m

Revenue growth, %

269%(48%)19%

Cost of goods sold

23 k918 k922 k511 k

Gross profit

2.5 m8.3 m3.9 m5.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

5.5 m1.9 m475 k462 k1.3 m626 k464 k4.3 m

Cost of goods sold

75 k485 k233 k509 k142 k233 k93 k111 k

Gross profit

5.4 m1.4 m242 k(47 k)1.1 m393 k371 k4.2 m

Gross profit Margin, %

99%74%51%(10%)89%63%80%97%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

21.4 m11.4 m3.9 m2.1 m

Accounts Receivable

59 k678 k519 k530 k

Inventories

336 k275 k469 k764 k

Current Assets

22.3 m13.3 m6.3 m3.6 m
USDQ2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

17.4 m16.2 m7.4 m5.8 m6.9 m2.7 m5.6 m3.8 m

Accounts Receivable

49 k513 k664 k575 k688 k687 k398 k

Inventories

377 k217 k411 k142 k405 k778 k800 k

Current Assets

18.8 m18 m9.8 m8.2 m9.1 m4.9 m7.2 m5.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(16.9 m)(21.8 m)(19 m)(7.4 m)

Depreciation and Amortization

77 k170 k300 k289 k

Accounts Receivable

253 k(620 k)159 k(11 k)

Inventories

(341 k)61 k(194 k)(295 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.4 m)(4.5 m)(6.4 m)(5 m)(2.5 m)(3.3 m)(1.3 m)8.1 m

Depreciation and Amortization

40 k102 k

Accounts Receivable

10 k(770 k)513 k664 k575 k688 k687 k398 k

Inventories

(41 k)15 k217 k411 k142 k405 k778 k800 k
Y, 2017

Financial Leverage

6.4 x
Show all financial metrics

Apricus Biosciences Market Value History

Traffic Overview of Apricus Biosciences

Apricus Biosciences Online and Social Media Presence

Apricus Biosciences News and Updates

BRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals

* Apricus biosciences inc says apricus and sandoz agree to mutually terminate license agreement

Apricus Biosciences Company Life and Culture

You may also be interested in